Navigation Links
Intellikine Appoints William Rohn to its Board of Directors
Date:2/23/2010

LA JOLLA, Calif., Feb. 23 /PRNewswire/ -- Intellikine, Inc., a leader in the development of drugs against the PI3K/mTOR pathway, today announced that William R. Rohn has joined the company's board of directors.

Mr. Rohn has over 30 years of management experience in the biotechnology and pharmaceutical industry, including more than 10 years in executive management positions at IDEC Pharmaceuticals and Biogen Idec, where he served as Chief Operating Officer until his retirement in 2005.  He joined IDEC in 1993 as Senior Vice President, Commercial and Corporate Development, was appointed Senior Vice President, Commercial Operations and was promoted to Chief Operating Officer in 1998. In 2002, he became President, responsible for Sales, Marketing, Business Development, Manufacturing, Quality, Medical Affairs and CMC Regulatory Affairs.  He was responsible for building IDEC's commercial infrastructure to support the launch of Rituxan, the first monoclonal antibody approved in the U.S. for the treatment of cancer.  Mr. Rohn serves on the boards of directors of Elan Corporation, plc, Cerus Corporation, and Cebix, Inc.

"We are delighted to welcome Bill Rohn to Intellikine's board of directors," said Troy Wilson, Ph.D., J.D., President and CEO of Intellikine.  "His strategic insights and experience in growing biotechnology companies, including his experience transitioning IDEC from a development stage company to a very successful commercial enterprise, will be invaluable to Intellikine as we seek to advance our growing pipeline of drugs against the PI3K/mTOR pathway."

"Intellikine has rapidly built one of the best pipelines against the PI3K/mTOR pathway," said William Rohn.  "I am excited about the opportunity to work with the management team and board to build the company and, in particular, to forge industry-leading partnerships to develop and commercialize the company's products for the treatment of cancer, inflammation and other serious diseases."

About Intellikine

Intellikine is a private, clinical-stage company focused on the discovery and development of innovative small molecule drugs targeting the PI3K/mTOR pathway.  Intellikine recently announced the start of a Phase I trial for INK128, a selective TORC1/2 inhibitor for oncology and is advancing INK1197, a PI3K-delta/gamma dual-selective inhibitor for the treatment of inflammatory and respiratory diseases.  Other programs include PI3K-delta/gamma dual-selective inhibitors for oncology, PI3K-alpha/beta selective inhibitors for oncology, as well as other isoform-selective inhibitors. Intellikine has raised $41 million from an outstanding group of life science investors including Abingworth, Sofinnova Ventures, CMEA Capital, Novartis Venture Funds, U.S. Venture Partners, Biogen Idec and FinTech Global Capital.  In addition, Intellikine has a commitment, subject to fulfillment of certain conditions, for another $22.5 million in equity financing from its current investors.  For more information, please visit the company's website at www.intellikine.com.

SOURCE Intellikine, Inc.

Back to top

RELATED LINKS
http://www.intellikine.com

'/>"/>

SOURCE Intellikine, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aton Pharma Appoints Dr. Wayne Mulcahy to Vice President, Clinical Operations
2. TechTeam Global Appoints Life Sciences Services Director
3. ADVENTRX Appoints Icahn Representative to Board of Directors
4. MS&L Appoints Patricia Archambault as Vice President, Healthcare in Montreal
5. Encorium Re-Appoints Dr. Kai Lindevall as Chief Executive Officer and Appoints Current Director, Shahab Fatheazam, Chairman of the Board
6. Avantium Appoints Gunnar Staaf as CEO Pharma
7. In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors
8. Millstone Medical Outsourcing Appoints New Leadership of Memphis Facility
9. Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer
10. Jazz Pharmaceuticals Appoints Kathryn Falberg as Chief Financial Officer
11. Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural Health ... Structural electronics involves electronic and/or electrical ... structures, replacing dumb structures such as vehicle bodies ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):